Elanco Animal Health, Inc. Stock

$14.29

0.07% yesterday

NYSE, Jun 27, 10:13 pm CET

ISIN

US28414H1032

Symbol

ELAN

Reports

Quarter | Annual

Index

NYSE Composite

Overview Dividends Analysts Charts News Strategies

Elanco Animal Health, Inc. Stock price

$14.29

-6.71 31.95% 5Y

NYSE, Closing price Fri, Jun 27 2025

-0.01 0.07%

ISIN

US28414H1032

Symbol

ELAN

Reports

Quarter | Annual

Index

NYSE Composite

Key metrics

Basic

Market capitalization

$7.1b

Enterprise Value

$11.0b

Net debt

$3.9b

Cash

$487.0m

Shares outstanding

496.5m

Valuation (TTM | estimate)

P/E

19.05 | 16.70

P/S

1.60 | 1.53

EV/Sales

2.49 | 2.38

EV/FCF

33.05

P/B

1.12

Financial Health

Equity Ratio

48.33%

Return on Equity

5.54%

ROCE

2.05%

ROIC

1.48%

Debt/Equity

0.69

Financials (TTM | estimate)

Revenue

$4.4b | $4.6b

EBITDA

$761.0m | $870.7m

EBIT

$239.0m

Net Income

$373.0m | $424.8m

Free Cash Flow

$333.0m

Growth (TTM | estimate)

Revenue

1.42% | 4.28%

EBITDA

-3.06% | 11.92%

EBIT

0.42%

Net Income

128.65% | 25.68%

Free Cash Flow

19.78%

Margin (TTM | estimate)

Gross

54.89%

EBITDA

17.19% | 18.81%

EBIT

5.40%

Net

8.43% | 9.18%

Free Cash Flow

7.52%

EPS

$0.75

FCF per Share

$0.67

Short interest

6.76%

Employees

9.23k

Rev per Employee

$480.00k

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Elanco Animal Health, Inc. Stock Analysis

Unlock Scores for Free

??

21 Analysts have issued a Elanco Animal Health, Inc. forecast:

13x Buy

62%

8x Hold

38%

More details on Analyst Estimates Including Price Targets

21 Analysts have issued a Elanco Animal Health, Inc. forecast:

Buy

62%

Hold

38%

Analyst Estimates with Stock Price Targets

Financial data from Elanco Animal Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	4,427 4,427	1% 1% 100%
- Direct Costs	1,997 1,997	2% 2% 45%
Gross Profit	2,430 2,430	1% 1% 55%
- Selling and Administrative Expenses	1,318 1,318	2% 2% 30%
- Research and Development Expense	351 351	5% 5% 8%
EBITDA	761 761	3% 3% 17%
- Depreciation and Amortization	522 522	5% 5% 12%
EBIT (Operating Income) EBIT	239 239	0% 0% 5%
Net Profit	373 373	129% 129% 8%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Elanco Animal Health, Inc. Stock News

Neutral

PRNewsWire

●

one day ago

Elanco Releases 2024 Impact Report and Introduces New Framework

GREENFIELD, Ind. , June 26, 2025 /PRNewswire/ -- Today, Elanco Animal Health Incorporated (NYSE: ELAN) announced the release of its 2024 Impact Report, showcasing its efforts to enhance animal care, not just improving the lives of animals but also the people who care for them.

Neutral

PRNewsWire

●

16 days ago

Elanco Receives Positive Opinion on Zenrelia (ilunocitinib) from EU's Committee for Veterinary Medicinal Products (CVMP)

Company expects approval and product supply in market before the end of third quarter GREENFIELD, Ind. , June 12, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Zenrelia™ (ilunocitinib) has been granted a positive opinion by the European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP), paving the way for the product's marketing aut...

Neutral

PRNewsWire

●

23 days ago

Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief

The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief. Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in the year.1 Allergy season makes itch worse, with 83% of pet owners saying that increased pollen leve...

More Elanco Animal Health, Inc. News

Company Profile

Elanco Animal Health, Inc. engages in the innovation, development, manufacture and market products for companion and food animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded on May 3, 2018 and is headquartered in Greenfield, IN.

Head office	United States
CEO	Jeffrey Simmons
Employees	9,225
Founded	1954
Website	www.elanco.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now